Perioperative Management of Antiplatelet-Drugs in Cardiac Surgery

Raquel Ferrandis*, Juan V. Llau and Ana Mugarra

Department of Anaesthesiology and Critical Care Medicine, Hospital Clínic Universitari, València, Spain

Abstract: The management of coronary patients scheduled for a coronary artery bypass grafting (CABG), who are receiving one or more antiplatelet drugs, is plenty of controversies. It has been shown that withdrawal of antiplatelet drugs is associated with an increased risk of a thrombotic event, but surgery under an altered platelet function also means an increased risk of bleeding in the perioperative period. Because of the conflict recommendations, this review article tries to evaluate the outcome of different perioperative antiplatelet protocols in patients with coronary artery disease undergoing CABG.

1. INTRODUCTION

The incidence of coronary artery disease (CAD) is high and increasing. First treatment of occlusive coronary disease involves percutaneous revascularization and many times one or more stents placement. Any percutaneous coronary intervention causes trauma to the vessel wall, rendering the endoluminal surface thrombogenic and thus, dual antiplatelet therapy (mostly aspirin and clopidogrel) is currently recommended [1, 2].

When these patients are scheduled for coronary artery bypass grafting (CABG), the traditional recommendation has been to stop antiplatelet drugs between 7 to 10 days prior to surgery [3]. But, withdrawal of aspirin in patients with CAD has been associated with a 2 to 4-fold increase in the risk of death and myocardial infarction [4], being the major independent predictor of stent occlusion [5, 6]. Thus, the anaesthesiologist faces the dilemma of stopping the antiplatelet treatment to avoid bleeding and risking postoperative stent thrombosis, or to maintain the antiplatelet therapy perioperatively to avoid the stent thrombosis, so risking major blood loss and increased transfusion rate.

We lack scientific evidence on the optimum perioperative therapy in such a situation. Because of the conflict recommendations, we undertook this systematic review of the literature to evaluate the outcome of different perioperative antiplatelet protocols in patients with CAD undergoing CABG.

2. MAIN CHARACTERISTICS OF ANTIPLATELET DRUGS

The well established current indications of antiplatelet drugs (APD) are shown in Table 1 [7, 8].

All of them are capable to inhibit platelet function, particularly activation and subsequent aggregation, although they make this effect through different ways showing different antiaggregant power (Table 2) [9, 10]. APD can be classified into four groups:

1. Adenosin diphosphate (ADP) receptor antagonists, such as the thienopyridine drugs ticlopidine and clopidogrel, which reach their peak of activity after 3-5 days, producing a prolonged antiaggregant effect (7-10 days) due to its long half-life. The inhibitory effects of
Table 2. Antiaggregant Effect of Some of the Antiplatelet Drugs

| Drug                             | Complete Reversal Time (days) | Antiaggregant Effect |
|---------------------------------|-------------------------------|----------------------|
| **Adenosin Diphosphate Receptor Antagonists** |                               |                      |
| Ticlopidine                      | 10-14                         | High                 |
| Clopidogrel                      | 7-10                          | High                 |
| **GPIIb/IIIa Receptor Antagonists** |                               |                      |
| Eptifibatide                     | 4 hours                       | High                 |
| Tirofiban                        | 4 hours                       | High                 |
| Abciximab                        | 48-72 hours                   | High                 |
| **Inhibitors Of Ciclooxygenase 1 Enzyme (COX-1)** |                               |                      |
| ASA                              | 7                             | High                 |
| Piroxicam                        | 7                             | High                 |
| Indomethacin                     | 3                             | High                 |
| Ketorolac                        | 2                             | High                 |
| Flurbiprofen                     | 1                             | High                 |
| Ibuprofen                        | 1                             | Moderate             |
| Naproxen                         | 2                             | Moderate             |
| Ketoprofen                       | 1                             | Moderate             |
| Diclofenac                       | 1                             | Moderate             |
| Salsalate                        | < 1                           | Weak                 |
| Diflunisal                       | < 1                           | Weak                 |
| Paracetamol                      | < 1                           | Weak                 |
| Proparacetamol                   | < 1                           | Weak                 |
| Metamizol                        | < 1                           | Weak                 |
| Rofecoxib                        | 0                             | No                   |
| Celecoxib                        | 0                             | No                   |
| **Drugs That Increase The Intraplatelet Levels Of AMPc** |                               |                      |
| Trifusal                         | 7                             | High                 |
| Dipyridamole                     | 1                             | Moderate             |

clopidogrel could be attained earlier by using 300 or 600 mg loading dose. Moreover, 600 mg double bolus has been shown to achieve greater platelet inhibition than conventional single loading doses [11].

2. **GPIIb/IIIa receptor antagonists**, of exclusively intravenous use, which are more powerful, albeit with a shorter-lasting action (24 h): eptifibatide, abciximab, tirofiban.

3. **Drugs that increase the intraplatelet levels of AMPc**. The best known agent in this group is dipyridamole (moderate antiaggregant effect lasting about 24 hours). Other drugs are the I-2 prostaglandin (epoprostenol) and its analog iloprost, both used by intravenous route with a brief antiaggregant effect (< 3 h).

4. **Inhibitors of ciclooxygenase 1 enzyme (COX-1)**. The best known representatives are acetylsalicylic acid (ASA) and non-esteroidal anti-inflammatory drugs (NSAIDs). ASA is the most deeply studied one and its antiaggregant effect takes place with the irreversible blockade of COX-1, so its action lasts throughout all the life of the platelet (7-10 days). Nevertheless, from the third or fourth day usually there is enough number of platelets to guarantee suitable haemostasis. The NSAIDs also produce inhibition of platelet aggregation by a similar mechanism to the ASA, although there are two important differences: firstly the blocking effect of the COX-1 is reversible, thus once the drug has been eliminated from the circulation, the platelet function is restored; secondly, there is a great difference between the different NSAIDs in their capacity to inhibit COX-1 and, consequently, in its platelet antiaggregant action.

Actually the field of the indications of use of the APD is being continuously updated. In cardiology patients, some recent questions of development of the APD deserved to be highlighted:

- The role of the aspirin in the primary prevention has extended its prescription based on related factors of cardiovascular and/or neurological risk. Moreover the combination of two APD drugs (mainly ASA and clopidogrel) in high risk patients is a practice more and more extended [9].

- Dual antiplatelet therapy has to be maintained at least 12 months after drug eluting stent placement and elective surgery postponed; if surgery is necessary, at least ASA should be maintained throughout the perioperative period and the patient operated under its antiaggregant effect [12]. Probably, in this patient a specific protocol of antiaggregation in type, combination and duration of APD need to be applied [13, 14].

- The interindividual response to the APD is evident and it does not seem that a valid universal pattern of antiaggregation for all the patients exists.

Then, we face different type of patients who benefit from antiplatelet therapy (Table 3) [15, 16]. From our point of view, we could distinguish two groups: patients with chronic treatment who are scheduled for cardiac surgery and patients who require urgent surgery, most of them with double antiaggregation.

3. CARDIOVASCULAR RISK AFTER ANTIPLATELET DRUGS WITHDRAWAL

The antiplatelet therapy in patients at high risk of occlusive vascular events reduce the combined outcome of any serious vascular event by about one quarter, non-fatal myocardial infarction by one third, non-fatal stroke by one quarter, and vascular mortality by one sixth (with no apparent adverse effect on other death) [17]. Aspirin has been the most widely studied APD, with doses of 75-150 mg daily at least as effective as higher daily doses. Keeping patients on aspirin prior to surgery may help to attenuate the inflammatory response during the operative period and may also reduce cardiovascular events while awaiting surgery [18].

As we have previously described, the platelet inhibition achieved with aspirin, although irreversible for target platelets, lasts until a significant pool of new platelets is produced. Nevertheless, a complete recovery of platelet aggregation has been observed by day 3 (in 50% healthy
young men) [19] which seems due in part of a biological platelet aggregation “rebound phenomenon”. In fact, after aspirin discontinuation, the recovery of cyclooxigenase activity may occur rapidly, with a heterogeneous synthesis of thromboxane A2 by fresh platelets [20], which may have possible hazardous effects in patients with cardiovascular disease [21]. Nevertheless, none of the guidelines support the assessment of platelet reactivity by using point-of-care devices.

Many studies have been recently published describing the cardiovascular risk of perioperative APD withdrawal, most of them in non-cardiac surgery, but we did not find any study comparing the cardiovascular risks of preprocedural APD withdrawal directly against APD continuation. Instead of it, we collect some studies that report the frequency of APD (aspirin) withdrawal preceding acute cardiovascular syndrome (Table 4) [4, 22-24].

Talking about clopidogrel, most guidelines would recommend cessation for 5-7 days before surgery. The CURE study [25] and its sub-analyses show that cessation of clopidogrel in these patients and for this time period is associated with a 1% increase in the risk of myocardial infarction. In non-surgical patients, with acute coronary artery syndrome, the first 90-day interval after stopping treatment with clopidogrel was associated with a significantly higher risk of adverse events (incidence rate ratio of 1.98) [26].

4. BLEEDING RISK WITH PERIOPERATIVE TREATMENT OF ANTIPLATELET DRUGS

There are many clinical studies comparing peri-procedural-bleeding risks with and without aspirin. Excluding studies on cardiac surgery, aspirin multiplied baseline-bleeding rate by a factor of 1.5 [24], although mortalities possibly caused by bleeding occurred only after transurethral prostatectomy [27] and intracranial neuro-surgery [28].

Focus on cardiac surgery, the results are heterogeneous but there seems to have an increase of bleeding with a tendency to need more transfusion requirements in patients under the effect of aspirin [29-35]. Thus, in a recent systematic review of randomized and observational studies [36], pre-operative aspirin maintenance was associated with a significant increase in the volume of post-operative bleeding (mean difference 114 ml) and transfusion requirements (mean difference 0.34 units), with significantly difference in the rates of reoperation; with the subgroup analysis, the authors conclude that this bleeding could be minimized by the use of aspirin doses less than 325 mg/day. Another metanalysis [37] shows similar results, highlighting that the rate of platelet transfusion was similar in both groups.

Bleeding complications and transfusion requirements could be lower if the CABG surgery is performed off-pump, and patients under the effect of aspirin seems to be at less

| Clinical Setting | Recommendation | Grade |
|------------------|----------------|-------|
| Ischaemic heart disease | Aspirin or clopidogrel (as alternative) | 1A |
| Chronic stable angina | Aspirin or clopidogrel + aspirin (more effective) | 1A |
| Acute coronary syndrome without ST-segment elevation with PCI Without PCI | Aspirin or clopidogrel + aspirin (more effective) i.v. GPIIb/IIIa inhibitors | 1A |
| Acute myocardial infarction with ST elevation | Aspirin i.v. GPIIb/IIIa inhibitors | 1A |
| Acute myocardial infarction with ST elevation and with primary PCI | Aspirin i.v. GPIIb/IIIa inhibitors | 1A |
| Prior myocardial infarction | Aspirin or clopidogrel (as alternative) | 1A |
| Elective PCI | Aspirin | 1A |
| Elective PCI + stent application | Clopidogrel or ticlopidine | 1A |
| | i.v. GPIIb/IIIa inhibitors | 2A |

PCI: Percutaneous coronary intervention. Grades of recommendation as defined by Guyatt et al. [16].

Table 4. Aspirin Withdrawal Preceding Acute Cardiovascular Syndrome

| Studies (Author, Year) | Number of Patients Admitted for ACS | % Patients with Recent Withdrawal of APD | % Withdrawal for Surgery | Time between Withdrawal Aspirin and ACS |
|------------------------|-------------------------------------|----------------------------------------|--------------------------|----------------------------------------|
| Collet, 2004           | 1358                                | 73(5.4%)                               | 74.38%                   | 11.9±0.8                               |
| Collet, 2000           | 475                                 | 11(2.3%)                               | 81%                      | 10                                     |
| Ferrari, 2005          | 1236                                | 51(4.1%)                               | 13.72%                   | 10±1.9                                 |

ACS: acute cardiovascular syndrome
risk for bleeding or for reoperation due to postoperative haemorrhage [38], even if aspirin is associated with clopidogrel and not discontinued within 2 days of surgery (no differences with the discontinuation more than 6 days before surgery or between 2 and 5 days before surgery) [39]. Moreover, some articles have associated preoperative aspirin maintenance with a decreased risk of mortality in CABG patients without significant increase in haemorrhage, blood product requirements, or related morbidities [40], even with aspirin usage within the 5 days preceding surgery [41].

Thus, some surgical and patients characteristics as older age, smaller body mass index, non-elective cases, 5 or more distal anastomosis are more important risk factors for re-exploration for bleeding after CABG than aspirin ingestion, which is consistent with other previous studies [42, 43].

The other common drugs used as antiplatelet agent are thienopyridines that antagonize irreversibly the platelet adenosine diphosphate. It has showed to increase bleeding after CABG in many articles [44-48], although there is another report in which the maintenance of clopidogrel does not increase bleeding or transfusion requirements [49]. The optimal waiting period after last clopidogrel administration is not known but appears to be at least 5 days before CABG [50]; if the patient need to be antiaggregated near before cardiac surgery, probably the best option is to use low-dose aspirin perioperatively, once clopidogrel has been discontinued [51]. Finally, it has been published that a combined preoperative treatment with heparin infusion could prevent the increased blood loss associated to the administration of clopidogrel, which may have been attributable to a conservation of coagulation factors, as evidenced by the increased plasma fibrinogen concentrations with combined prophylactic treatment [52].

Other drugs that have become increasingly common are the intravenous GP IIb/IIIa platelet receptor antagonist (tirolfiban, eptifibate and abciximab). While eptifibatide and tirofiban have a competitive binding and are rapidly cleared, with an almost recovered platelet function in about 4 hours [53], abciximab causes prolonged and irreversible effect, with inhibition of platelet function and aggregation lasting 24-48 hours [53]. Transfusion of platelets rapidly reverses the inhibitory effects of abciximab [54], but it is of very little utility during infusion or suddenly after eptifibatide or tirofiban. No data are available in the literature on the impact of tirofiban or eptifibatide treatment on emergency CABG; however their short half-life and short-lasting action after stopping the infusion is a potential advantage for the performance of CABG with reduced risk of bleeding [55-58], so no delay in surgery has been recommended [59]. In patients treated with abciximab, delaying emergency or urgent CABG for 12 hours has been recommend [59, 60], but other authors suggest rapid discontinuation of abciximab infusion and undelayed intervention [61, 62]. In any case, platelet transfusion should be considered only when increased bleeding is encountered (not prophylactically), and only after cessation of cardiopulmonary bypass [63].

4.1. Methods to Avoid Bleeding

In cardiac surgery, we should also take care of a variety of methods intended to minimize perioperative transfusion: preoperative autologous donation, intra- and postoperative cell salvage, and the use of drugs, such as aprotinin (a protease inhibitor), desmopressin (that induces the release of factor VIIIvWF) and tranexamic acid (TXA) and epsilon-aminocaproic acid (EACA) (that mainly inhibit plasmin binding to fibrin).

Many studies have shown that aprotinin decreased the number of allogenic transfusions after cardiac surgery and the proportion of patients requiring reoperation because of bleeding [64]. Recent publications, however, have questioned the safety of this agent, reporting not only an increase in renal impairment but an increased risk of long-term mortality following CABG surgery [65-67]. The FDA and the EMEA have recently suspended its use, pending of a complete analysis of a randomized prospective trial in Canada (BART trial), which has shown similar results in terms of mortality.

Desmopressin has not shown a statistically significant effect on reducing the proportion of patients receiving transfusion after CABG [64], but its efficacy seemed to vary depending on the use of aspirin. While some authors have shown that desmopressin reduced the postoperative blood loss and the transfusion requirements in patients treated with aspirin within 7 to 5 days before surgery compared to placebo [68-70], no effect was found in patients treated within 2 days before CABG [71].

The TXA decreases the portion of patients receiving allogenic blood, but has not statistically significant effect on reoperations because of bleeding [64], both in on- and in off-pump surgery [72]. This effect is no consistent in all the studies, excluding patients with APD, prophylactic use of TXA did not result in any significant decrease in postoperative bleeding in one study [73], but reduced postoperative bleeding and fibrinolysis in another [74]. In patients treated with aspirin, the administration of a single dose of TXA (30 mg/kg) immediately before cardiopulmonary bypass significantly reduced postoperative bleeding and inhibited fibrinolysis [75].

There are very few studies with EACA that have not shown any statistically significant effect [64].

4.2. Monitors of Platelet Function Perioperatively

The current standard of care for perioperative coagulation monitoring consists of a platelet count and prothrombin (PT) and activated partial thromboplastin (aPTT) times, omitting platelet function. However, these routine tests are insensitive predictors of bleeding and perioperative changes in platelet count shows poor correlation with changes in platelet function [76]. It would be helpful in the perioperative management of APD to have a haemostatic test to identify the patients at bleeding risk because of platelet dysfunction related with the administration of any APD.

Several tests could be used to assess the platelet function. Optical platelet aggregometry is considered at present the reference assay for diagnosis of platelet disorders [12], although it is not completely standardized, the laboratory work up is complex and it is not possible to be performed immediately before the surgery. The Platelet Function Analyser (PFA-100) explores the platelet adhesive capacity,
measuring the closure time taken for a platelet plug to occlude an aperture in a membrane impregnated with collagen and epinephrine or ADP [77]; ASA and clopidogrel have been shown to prolong this closure time, but without evident correlation with a perioperative bleeding. The Plateletworks™ analyser measures the percentage of aggregation of whole blood before and after the exposure to ADP; its results are contradictory when compared with optical aggregometry: good correlation for clopidogrel [78] but of limited use for ASA [79]. Thromboelastography (TEG) is a whole blood coagulation monitor, which can demonstrate the alteration of platelet aggregation, but is unable to detect the defects that occur with ASA or demonstrate the ADP blockade caused by clopidogrel.

Unfortunately any of these tests has good correlation with perioperative bleeding and further clinical investigations are necessary in this field, although they can help us to reduce the rate of reoperation for bleeding (TEG), in part by helping to differentiate surgical from nonsurgical bleeding [80], or to improve appropriate platelet transfusion (PFA-100) [81].

5. GUIDELINES AND RECOMMENDATIONS

The management of patients under the effect of antiaggregant agents scheduled for cardiac surgery is a major topic of interest and concern for all perioperative caregivers. Many recommendations could be found in the available published papers [8, 13, 14, 36, 37, 51, 82-85] and they could be summarized as follows:

1. Patient Treated with Aspirin
   • Aspirin should be maintained in patients at high risk for arterial thrombotic complications. The optimal dose of aspirin ranges between 75 and 325 mg and in the perioperative period, in the majority of patients, it would be enough the maintenance of low-dose of aspirin.
   • In the case of high risk of bleeding, some drugs that decrease postoperative bleeding, as TXA or EACA (with limited evidence to support the use of one agent over the other) could be used; desmopresine might be considered preoperatively only in patients with acquired or inherited defects in primary haemostasis detected by abnormal point-of-care test, as PFA-100.

2. Patient Treated with Clopidogrel
   • If the patient is on treatment with clopidogrel and needs to be antiaggregated near before cardiac surgery, probably the best option is to discontinue clopidogrel (at least 5 days before surgery) and use low-dose aspirin perioperatively (75-125 mg daily).
   • Dual antiplatelet therapy is associated with too high bleeding risk. If it is mandatory to maintain this protocol before surgery (probably only in patients with a drug-eluting stent implanted less than 12 months ago), and because of the concerns about premature discontinuation of clopidogrel in these very high thrombotic risk patients, several algorithms have been proposed, including the administration of an intravenous glycoprotein IIb/IIIa inhibitor or unfractionated heparin as “bridging therapy”. At present, there is no enough evidence-based date to support this strategy.

3. Patient Treated with GP IIb/IIIa Inhibitor
   • In emergency surgery, if the patient is under the effect of a glycoprotein IIb/IIIa inhibitor, it might be considered the platelet transfusion (mainly if it is abciximab) if there is too much bleeding; due to the short-acting time of eptifibatide or tirofiban, the delay of surgery is not recommended in the case of previous administration of them.

4. Postoperative Treatment
   • If aspirin therapy has been interrupted before surgery, it should be administered early after surgery, always within 48 hours after CABG, and preferably within 6 hours after surgery. Dose ranges between 150-325 mg/day; optimal benefit could be reach with 325 mg/day, at least the first year.
   • There is no specific recommendation for resuming clopidogrel after surgery, and it seems to have no superiority over aspirin; if it is indicated instead of aspirin, the timing for its administration could be the same as for aspirin, but it is not recommended a loading dose (300-600 mg) if first administration is close after surgery.

5. Others
   • Blood salvage techniques use must be encouraged, as the devices that conserve blood (intraoperative blood salvage) or the use of autologous blood predonation or normovolaemic haemodilution.
   • Platelet transfusion is not indicated as prophylaxis to avoid bleeding, even if the patient is under the effect of aspirin or clopidogrel, and its administration must be reserved if necessary to control excessive bleeding.
   • It is necessary an optimal preparation of the patient, avoiding anaemia stimulating the administration of drugs that increase preoperative blood volume, as erythro-poietin in combination with iron.
   • Several guidelines recommend a multimodality approach to blood conservation with the setting-up of consensus algorithms and point-of-care testing.

6. CONCLUSIONS

The handicap of management of antiplatelet agents in the perioperative period of cardiac surgery requires close collaboration between cardiologists, surgeons and anaesthesiologists. It is necessary to avoid thrombotic complications maintaining the antiaggregation, but balancing bleeding complications.

Patients treated with long-term APD could be at risk for increased bleeding if it is maintained until surgery, mainly if
there are any other outstanding variable as indicator of risk: advanced age, preoperative anaemia, reoperative o complex procedures, emergency operations or non-cardiac patient co-morbidities. If the patient is under the effect of one or more of these drugs the associated bleeding risk might be carefully balanced and an alternative antiaggregation protocol could be considered. Moreover, the drugs to minimize bleeding could play an important role and might be in consideration.

The decision to stop the APD some days before surgery faces up to the decision to maintain the treatment up to surgery. The choice for one or the other option should be based on the individual balance between the risk to develop any cardiovascular event if the APD has been withdrawn and the complications associated as result of the major bleeding if the APD has been maintained until the day of the surgery.

Summarising both possibilities and the comments stated above, we know that clopidogrel maintenance prior to cardiac surgery is associated with a more blood product usage, a 2-5 fold increase in the risk of re-exploration and 30-100% increase in the chest drain blood loss. The withdrawal of clopidogrel prior to surgery, between 5 and 7 days, could be associated with a little increase of the risk of myocardial infarction, estimated around 1% while the patient is waiting for surgery [84]. Between patients under aspirin, its withdrawal 2-3 days before surgery could reduce perioperative blood loss, risk for transfusion and reoperation for bleeding. This practice seems safe for patients without acute coronary syndromes, but for urgent cardiac surgery, the risk of perioperative infarction is higher and the balance is favourable to the maintenance of aspirin up to the day of surgery.

So, for patients scheduled for CABG, the recommendation is to stop clopidogrel at least 5 days and, preferably, 10 days prior to surgery to minimize blood loss. In the case of aspirin, the recommendation is to maintain it up to surgery and beyond the time of surgery. But in the case of patients, who are not at high risk for cardiac events, the routine recommendation is to stop aspirin or clopidogrel prior to surgery because of risk of bleeding and morbi-mortality associated in these patients [85].

REFERENCES

[1] Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804-47.
[2] Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz JL. Antiplatelet therapy during percutaneous coronary intervention: The Seventh ACCP Conference on Antiplatelet and Thrombolytic Therapy. Chest 2004; 124: 576S-99S.
[3] Bojar RM. In: Manual of Perioperative Care in Adult Cardiovascular Surgery. Blackwell, Malden, Oxford, 2005
[4] Collet JP, Montalescot G, Balchet B, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 2004; 110: 2361-67.
[5] Ia Kovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-30.
[6] Ferrari E, Bendhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: an especial risk for late stent thrombosis. J Am Coll Cardiol 2005; 45: 456-9.
[7] Samama CM, Bastien O, Forestier F, et al. Antiplatelet agents in the perioperative period: expert recommendations of the French Society of Anesthesiology and Intensive Care (SFAR) 2001 – Summary statement. Can J Anaesth 2002; 49: S26-S35.
[8] Lecompte T, Hardy JD. Antiplatelet agents and perioperative bleeding. Can J Anaesth 2006; 53: S103-S12.
[9] Patrono C, Coller B, Fitzgerald GA, Hirsh J, Roth G. Platelet active drugs: the relationships among dose, effectiveness and side effects. Chest 2004; 124: 2345-64S.
[10] Hirsh J, Warkenin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64S-94S.
[11] L’Allier PL, Ducrocq G, Pranno N, et al. Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens. Results from PREPAIR randomized study. J Am Coll Cardiol 2008; 51: 1066-72.
[12] Servin F. Low-dose aspirin and clopidogrel: how to act in patients scheduled for day surgery. Curr Opin Anaesthesiol 2007; 20: 531-4.
[13] Albaladejo P, Marret E, Pirioiu V, Samama CM. Perioperative management of antiplatelet agents in patients with coronary stents: recommendations of a French Task Force. Br J Anaesth 2006; 97: 580-84.
[14] Dalal AR, D’Souza S, Shulman RS. Brief review: Coronary drug-eluting stents and anasthesia. Can J Anaesth 2006; 53: 1230-43.
[15] The Task Force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Expert consensus document on the use of antiplatelet agents. Eur Heart J 2004; 25: 166-81.
[16] Guyatt G, Schunemann H, Cook D, et al. Grade of recommendation for antiplatelet agents. Chest 2001; 119: 3S-7S.
[17] Antithrombotic Trials’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
[18] Sun JCJ, Whitlock RW, Cheng J, et al. The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. Eur Heart J 2008; 1087-71.
[19] Jimenez AH, Stulbs ME, Tofler GH, Windler K, Williams GH, Muller JE. Rapidity and duration of platelet suppression by enteric-coated aspirin in healthy young men. Am J Cardiol 1992; 69: 258-62.
[20] McDonald JW, Ali M. Recovery of cyclooxygenase activity after aspirin in populations of platelets separated on stractan density gradients. Prostaglandins Leukot Med 1983; 12: 245-52.
[21] Beving H, Zhao C, Albage A, Ivert T. Abnormally high platelet activity after discontinuation of acetylsalicylic acid treatment. Blood Coagul Fiberinolysis 1996; 7: 80-4.
[22] Collet JP, Himbert F, Stig PG. Myocardial infarction after aspirin cessation in stable coronary artery disease patients. Int J Cardiol 2005; 76: 257-8.
[23] Burguer W, Chemmitius JM, Kneissl GD, Rücker G. Low-dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation– review a meta-analysis. J Intern Med 2005; 257: 399-414.
[24] Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non ST-elevation acute coronary syndrome: th Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004; 110: 1202-8.
[25] Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008; 299: 532-9.
[26] Thurstorn AV, Briant SL, Aspin and post-prostatectomy haemorrhage. Br J Urol 1993; 71: 574-6.
[27] CPMag, Sparrow OC, Ianotti F. Postoperative hematoma: a 5-year survey and identification of avoidable risk factors. Neurosurgery 1994; 35: 1061-4.
[28] Weightman WM, Gibbons NM, Weidmann CR, et al. The effect of preoperative aspirin-free interval on red blood cell transfusion requirements in cardiac surgical patients. J Cardiothorac Vasc Anesth 2002; 16: 54-8.
Transfusion in coronary artery surgery. Eur J Cardiothorac Surg 2004; 25: 419-23.

Lehmer JR, Stanford W, Bonney SL, et al. Aprotinin in coronary artery bypass surgery: effects on safety, efficacy, and influence on early saphenous vein graft patency-a multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994; 107: 543-51.

Pleyh M, Stenseth R, Wahba A, et al. The effect of preoperative clopidogrel on bleeding after coronary artery bypass grafting. Eur J Cardiothorac Surg 2005; 28: 54-60.

Saddi A, Nayyar M, et al. Enhanced efficacy of epifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. Circulation 2000; 102: 2952-8.

Von Heymann C, Redlich U, et al. Aprotinin for aprotinin on outcome after coronary artery bypass grafting. N Engl J Med 2008; 358: 784-93.

Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008; 358: 771-83.

Shaw AD, Stafford-Smith M, White WD, et al. The effect of aprotinin on outcome after coronary artery bypass grafting. N Engl J Med 2008; 358: 771-83.

Havek M, Grabenwoger F, Schneider J, et al. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg 2004; 128: 442-48.

Kalogeros A, Tayyarere C, Prette R, Di Dio P, Sezerman O. Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization. Eur J Cardiothorac Surg 1994; 8: 651-6.
Casati V, Della Valle P, Benussi S, et al. Effects of tranexamic acid on postoperative bleeding and related hematocellular variables in coronary surgery: comparison between on-pump and off-pump techniques. J Thorac Cardiovasc Surg 2004; 128: 83-91.

Andreasen JJ, Nielsen C. Prophylactic tranexamic acid in elective, primary coronary artery bypass surgery using cardiopulmonary bypass. Eur J Cardiothorac Surg 2004; 26: 311-7.

Santos ATL, Kalil RAK, Bauemann C, Pereira JB, Nesralla IA. A randomized, double-blind, and placebo-controlled study with tranexamic acid of bleeding and fibrinolytic activity after primary coronary artery bypass grafting. Braz J Med Biol Res 2006; 39: 63-9.

Pleym H, Stenseth R, Wahba A, Bjella L, Karevold A, Dale O. Single-dose tranexamic acid reduces postoperative bleeding after coronary surgery in patients treated with aspirin until surgery. Anesth Analg 2003; 96: 923-8.

Sié P, Steib A. Central laboratory and point of care assessment of perioperative hemostasis. Can J Anesth 2006; 53: S12-20.

Howard-Alpe GM, de Bono J, Hudsmit L, Orr WP, Foex P, Sear JW. Coronary artery stents and con-cardiac surgery. Br J Anaesth 2007; 98: 560-74.

Craft RM, Chavez JJ, Snider CC, Muenchen RA, Carroll RC. Comparison of modified thrombelastograph and plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. J Lab Clin Med 2005; 145: 309-15.

Lennon MJ, Gibbs NM, Weighman WM, McGuire D, Michalopoulos N. A comparison of Plateletworks™ and platelet aggregometry for the assessment of aspirin-related platelet dysfunction in cardiac surgical patients. J Cardiothorac Vasc Anesth 2004; 18: 136-40.

Essell JH, Martin TJ, Salinas J. Comparison of thromboelastography to bleeding time and standard coagulation tests in patients after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1993; 7: 410-5.

Hertfelder HJ, Bös M, Weber D, Winkler K, Hanfland P, Preusse CJ. Perioperative monitoring of primary and secondary haemostasis in coronary artery bypass grafting. Semin Thromb Hemost 2005; 31: 426-40.

Ferraris VA, Ferraris SP, Saha SP, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: The society of thoracic surgeons and society of cardiovascular anesthesiologists clinical practice guideline. Ann Thorac Surg 2007; 83: S27-86.

Chassot PG, Delabays A, Spanh DR. Perioperative antplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. Br J Anaesth 2007; 99: 316-28.

Dunning J, Versteegh M, Fabbi A, et al. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg 2008; 34: 73-92.

Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy. Chest 2008; 133: 399-399S.